[go: up one dir, main page]

AU6711994A - Rapamycin conjugates and antibodies - Google Patents

Rapamycin conjugates and antibodies

Info

Publication number
AU6711994A
AU6711994A AU67119/94A AU6711994A AU6711994A AU 6711994 A AU6711994 A AU 6711994A AU 67119/94 A AU67119/94 A AU 67119/94A AU 6711994 A AU6711994 A AU 6711994A AU 6711994 A AU6711994 A AU 6711994A
Authority
AU
Australia
Prior art keywords
antibodies
rapamycin conjugates
rapamycin
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU67119/94A
Inventor
Thomas Joseph Caggiano
Craig Eugene Caufield
Amedeo Arturo Failli
Katherine Lu Molnar-Kimber
Timothy Donald Ocain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of AU6711994A publication Critical patent/AU6711994A/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU67119/94A 1993-04-23 1994-04-22 Rapamycin conjugates and antibodies Abandoned AU6711994A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5303093A 1993-04-23 1993-04-23
US053030 1993-04-23
US22420794A 1994-04-14 1994-04-14
US224207 1994-04-14
PCT/US1994/004463 WO1994025072A1 (en) 1993-04-23 1994-04-22 Rapamycin conjugates and antibodies

Publications (1)

Publication Number Publication Date
AU6711994A true AU6711994A (en) 1994-11-21

Family

ID=26731365

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67119/94A Abandoned AU6711994A (en) 1993-04-23 1994-04-22 Rapamycin conjugates and antibodies

Country Status (2)

Country Link
AU (1) AU6711994A (en)
WO (1) WO1994025072A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40596E1 (en) * 1993-04-08 2008-12-02 Novartis Ag Rapamycin assay
GB9307491D0 (en) 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
AU740304B2 (en) * 1997-04-09 2001-11-01 Isotechnika Inc. Method for production of antibodies to specific sites of rapamycin
US6709873B1 (en) 1997-04-09 2004-03-23 Isodiagnostika Inc. Method for production of antibodies to specific sites of rapamycin
DK1319008T3 (en) * 2000-09-19 2009-02-09 Wyeth Corp Water-soluble rapamycin esters
PL1735321T3 (en) 2004-04-14 2009-04-30 Wyeth Corp Process for preparing rapamycin 42-esters and fk-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
US8021849B2 (en) 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
US7189582B2 (en) 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
CA2673296C (en) 2006-12-29 2012-10-16 Abbott Laboratories Improved assay for immunosuppressant drugs
CA2672972C (en) 2006-12-29 2015-06-23 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
CA2673314C (en) 2006-12-29 2014-03-11 Abbott Laboratories Non-denaturing lysis reagent for use with capture-in-solution immunoassay
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
FI3788049T3 (en) 2018-05-01 2023-05-30 Revolution Medicines Inc C40-, C28- AND C-32-LINKED RAPAMYCIN ANALOGUES AS MTOR INHIBITORS
MX2020011564A (en) 2018-05-01 2021-01-29 Revolution Medicines Inc RAPAMYCIN ANALOGUES BINDED TO C26 AS MTOR INHIBITORS.
SG11202012447YA (en) 2018-06-15 2021-01-28 Navitor Pharm Inc Rapamycin analogs and uses thereof
US11819476B2 (en) 2019-12-05 2023-11-21 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
TW202402277A (en) 2022-05-25 2024-01-16 美商銳新醫藥公司 Methods of treating cancer with an mtor inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98990A (en) * 1990-09-19 1992-08-31 American Home Prod PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID ESTERS OF RAPAMICIN
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5164495A (en) * 1991-09-18 1992-11-17 Abbott Laboratories Method for preparing a dicarboxylic acid half-acid ester of FK506
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
WO1993019752A1 (en) * 1992-04-07 1993-10-14 Dana-Farber Cancer Institute, Inc. Inhibition of p70 s6 kinase
WO1993025533A1 (en) * 1992-06-05 1993-12-23 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents

Also Published As

Publication number Publication date
WO1994025072A1 (en) 1994-11-10

Similar Documents

Publication Publication Date Title
AU7101094A (en) Factor ix - polymeric conjugates
AU6029594A (en) Factor viii - polymeric conjugates
AU5970194A (en) Stent
AU5306194A (en) Stent
DE69435044D1 (en) Rapamycin conjugates and antibodies
AU6109396A (en) Modular damper and structure with this damper
AU3811495A (en) Antibodies
AU7600496A (en) Interferon-polymer conjugates and process for preparing the same
AU6001594A (en) Imidazoazines
AU7109494A (en) Conjugated biodhesives
AU7446194A (en) 4-arylamino-benzopyran and related compounds
AU6711994A (en) Rapamycin conjugates and antibodies
AU7422496A (en) NM03 antibody materials and methods
AU4344696A (en) Oligonucleotide-dendrimer conjugates
AU6995594A (en) Aryltriflates and related compounds
AU5798394A (en) Thiadiazinones
AU6259294A (en) Life-savingfloat
AU7677194A (en) Sulfamethoxazole-specific immunosuppressive agents
AU8139594A (en) Microtome
AU6389494A (en) Tv-projector
AU1274295A (en) Heteroarylpyrroles
AU5188296A (en) Carbopeptoids and carbonucleotoids
AU7790594A (en) Proximity detectors
AU6159594A (en) Ashtray
AU5009993A (en) Isoprostane-protein conjugates